Daily use of consensus interferon: One-year treatment results for chronic hepatitis C patients relapsing or non-responding to previous interferon

Z. Karasu, Ahmet Gurakar, A. Jazzar, H. Wright

Research output: Contribution to journalArticle

Abstract

Background/aim: The optimal dose, duration and frequency of interferon treatment for chronic hepatitis C is not clear. Preliminary hepatitis C virus kinetic studies have suggested that daily interferon is more advantageous than thrice in a week administration. Recently, a synthetic recombinant interferon, consensus interferon, has been approved for clinical application. There is no data available about daily use of consensus interferon. Methods: Our study protocol was designed to investigate the efficacy of long-term (12 month) daily consensus interferon therapy for chronic hepatitis C patients, who have either relapsed or not responded to previous interferon therapy. Eleven patients were included in the study. Results: Overall, eight (72%) patients became serum HCV-RNA negative. Of these, 60% (3/5) were among previous non-responders and 83% (5/6) were among previous relapsers. Conclusions: Our preliminary data suggests that daily use of consensus interferon provides encouraging results in relapsers and non-responders. However, further time is needed to evaluate the sustained response rate.

Original languageEnglish (US)
Pages (from-to)191-195
Number of pages5
JournalTurkish Journal of Gastroenterology
Volume11
Issue number3
StatePublished - 2000
Externally publishedYes

Fingerprint

Chronic Hepatitis C
Interferons
Therapeutics
Hepacivirus
RNA
Serum

Keywords

  • Consensus interferon
  • Hepatitis C

ASJC Scopus subject areas

  • Gastroenterology

Cite this

@article{e5736482300d47c085b5243c63a19d57,
title = "Daily use of consensus interferon: One-year treatment results for chronic hepatitis C patients relapsing or non-responding to previous interferon",
abstract = "Background/aim: The optimal dose, duration and frequency of interferon treatment for chronic hepatitis C is not clear. Preliminary hepatitis C virus kinetic studies have suggested that daily interferon is more advantageous than thrice in a week administration. Recently, a synthetic recombinant interferon, consensus interferon, has been approved for clinical application. There is no data available about daily use of consensus interferon. Methods: Our study protocol was designed to investigate the efficacy of long-term (12 month) daily consensus interferon therapy for chronic hepatitis C patients, who have either relapsed or not responded to previous interferon therapy. Eleven patients were included in the study. Results: Overall, eight (72{\%}) patients became serum HCV-RNA negative. Of these, 60{\%} (3/5) were among previous non-responders and 83{\%} (5/6) were among previous relapsers. Conclusions: Our preliminary data suggests that daily use of consensus interferon provides encouraging results in relapsers and non-responders. However, further time is needed to evaluate the sustained response rate.",
keywords = "Consensus interferon, Hepatitis C",
author = "Z. Karasu and Ahmet Gurakar and A. Jazzar and H. Wright",
year = "2000",
language = "English (US)",
volume = "11",
pages = "191--195",
journal = "Turkish Journal of Gastroenterology",
issn = "1300-4948",
publisher = "Turkish Society of Gastroenterology",
number = "3",

}

TY - JOUR

T1 - Daily use of consensus interferon

T2 - One-year treatment results for chronic hepatitis C patients relapsing or non-responding to previous interferon

AU - Karasu, Z.

AU - Gurakar, Ahmet

AU - Jazzar, A.

AU - Wright, H.

PY - 2000

Y1 - 2000

N2 - Background/aim: The optimal dose, duration and frequency of interferon treatment for chronic hepatitis C is not clear. Preliminary hepatitis C virus kinetic studies have suggested that daily interferon is more advantageous than thrice in a week administration. Recently, a synthetic recombinant interferon, consensus interferon, has been approved for clinical application. There is no data available about daily use of consensus interferon. Methods: Our study protocol was designed to investigate the efficacy of long-term (12 month) daily consensus interferon therapy for chronic hepatitis C patients, who have either relapsed or not responded to previous interferon therapy. Eleven patients were included in the study. Results: Overall, eight (72%) patients became serum HCV-RNA negative. Of these, 60% (3/5) were among previous non-responders and 83% (5/6) were among previous relapsers. Conclusions: Our preliminary data suggests that daily use of consensus interferon provides encouraging results in relapsers and non-responders. However, further time is needed to evaluate the sustained response rate.

AB - Background/aim: The optimal dose, duration and frequency of interferon treatment for chronic hepatitis C is not clear. Preliminary hepatitis C virus kinetic studies have suggested that daily interferon is more advantageous than thrice in a week administration. Recently, a synthetic recombinant interferon, consensus interferon, has been approved for clinical application. There is no data available about daily use of consensus interferon. Methods: Our study protocol was designed to investigate the efficacy of long-term (12 month) daily consensus interferon therapy for chronic hepatitis C patients, who have either relapsed or not responded to previous interferon therapy. Eleven patients were included in the study. Results: Overall, eight (72%) patients became serum HCV-RNA negative. Of these, 60% (3/5) were among previous non-responders and 83% (5/6) were among previous relapsers. Conclusions: Our preliminary data suggests that daily use of consensus interferon provides encouraging results in relapsers and non-responders. However, further time is needed to evaluate the sustained response rate.

KW - Consensus interferon

KW - Hepatitis C

UR - http://www.scopus.com/inward/record.url?scp=0033732698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033732698&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0033732698

VL - 11

SP - 191

EP - 195

JO - Turkish Journal of Gastroenterology

JF - Turkish Journal of Gastroenterology

SN - 1300-4948

IS - 3

ER -